Biopharma company XenoPort has replaced its chief executive at a moment when the company is refocusing its strategic efforts, causing shares to rise 12%. 5 October 2015
The European Medicines Agency’s management board has nominated Guido Rasi as the executive director of the Agency. At an extraordinary session on October 1, the board selected Prof Rasi from a shortlist of candidates provided by the European Commission. 1 October 2015
German company leon-nanodrugs has appointed Theron Odlaug as chief executive and the chief executive of its newly-formed US subsidiary. 22 September 2015
Contract research and manufacturing organization Albany Molecular Research has made George Svokos chief operating officer, and Lori Henderson head of corporate business development. 14 September 2015
EMD Serono, the biopharma division of German pharma company Merck, has appointed Scott Filosi as senior vice president of managed markets. 10 September 2015
Autifony Therapeutics, a UK-based biotech company specializing in hearing loss and tinnitus, has appointed John Hutchison as chief medical officer. 3 September 2015
ACADIA Pharmaceuticals has submitted a New Drug Application to the US Food and Drug Administration seeking approval for Nuplazid (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. 3 September 2015
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024